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MaOBJECTIVES This multicenter, prospective, post-market surveillance study in Japan evaluates the paclitaxel-coated
Zilver PTX stent in real-world patients with complex lesions.
BACKGROUND The Zilver PTX stent is the ﬁrst drug-eluting stent (DES) approved for the superﬁcial femoral artery.
Previously, results from a large randomized study and a complementary, large single-arm study supported the safety and
effectiveness of the DES.
METHODS There were no exclusion criteria, and consecutive patients with symptomatic peripheral artery disease (PAD)
treated with the DES were enrolled in the study. Clinically driven target lesion revascularization (TLR) was deﬁned as
reintervention performed for $50% diameter stenosis after recurrent clinical symptoms of PAD. Clinical beneﬁt was
deﬁned as freedom from persistent or worsening symptoms of ischemia. Patency was evaluated by duplex ultrasound
where physicians considered this standard of care.
RESULTS In this study, 907 patients were enrolled at 95 institutions in Japan. There were numerous comorbidities
including high incidences of diabetes (58.8%), chronic kidney disease (43.8%), and critical limb ischemia (21.5%). Lesions
were also complex, with an average length of 14.7 cm, 41.6% total occlusions, and 18.6% in-stent restenosis. In total,
1,861 DES were placed in 1,075 lesions. Twelve-month follow-up was obtained for >95% of eligible patients. Freedom
from TLR was 91.0%, and clinical beneﬁt was 87.7% through 12 months. The 12-month primary patency rate was 86.4%.
CONCLUSIONS Despite more challenging lesions, results from the current study are similar to outcomes from the
previous Zilver PTX studies, conﬁrming the beneﬁt of the Zilver PTX DES in a real-world patient population.
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ABBR EV I A T I ON S
AND ACRONYMS
ABI = ankle brachial index
BMS = bare-metal stent(s)
CLI = critical limb ischemia
DCB = drug-coated balloon(s)
DES = drug-eluting stent(s)
ISR = in-stent restenosis
PAD = peripheral artery
disease
PTA = percutaneous
transluminal angioplasty
SFA = superﬁcial femoral
artery
TLR = target lesion
revascularization
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272E ndovascular treatment of symptom-atic peripheral artery disease (PAD)is the preferred revascularization
strategy when feasible. Percutaneous trans-
luminal angioplasty (PTA) has historically
been the most common endovascular treat-
ment option; however, restenosis rates
following PTA are high, resulting in frequent
revascularization procedures. In an effort to
reduce restenosis rates, a number of other
endovascular treatment options have been
developed, including atherectomy, bare-
metal stents (BMS), drug-coated balloons
(DCB), and drug-eluting stents (DES). Among
these, a paclitaxel-coated DES has success-
fully reduced restenosis and reintervention
rates for patients suffering from superﬁcialfemoral artery (SFA) disease (1,2).SEE PAGE 278A large randomized study in the United States,
Germany, and Japan demonstrated the safety and
effectiveness of the paclitaxel-coated DES for treating
SFA disease in patients with moderate lesions (mean
lesion length 6.5 cm) (1,2). A complementary single-
arm study in Europe, Korea, and Canada, further
supported the performance of the DES in a broader
patient population with more complex lesions (mean
lesion length 10.0 cm) (3). The current study evalu-
ates the safety and effectiveness of the paclitaxel-
coated DES in a large, real-world patient population
with long, complex lesions in Japan.
METHODS
This multicenter, prospective, post-market surveil-
lance study planned to enroll the ﬁrst 900 consecutive
patients with symptomatic PAD involving the above-
the-knee femoropopliteal arteries who were treated
with the Zilver PTX Drug-Eluting Peripheral Stent
(Cook Medical, Bloomington, Indiana) in Japan. This
DES is a self-expanding nitinol stent with a polymer-
free paclitaxel coating (3 mg/mm2 dose density). This
post-market surveillance study was required and
regulated by the Japanese Ministry of Health, Labour,
and Welfare, and was therefore required to be con-
ducted in accordance with Japanese Good Postmarket
Surveillance Practice Regulations, which dictate that
informed consent processes be determined by each
institution’s ethical committee policy to specify
whether informed consent was necessary or outcome
data could be abstracted while protecting patient’s
rights without requiring individual patient consent.BASELINE ASSESSMENT, INTERVENTIONS, AND
MEDICATIONS. Rutherford classiﬁcation and ankle
brachial index (ABI) were assessed pre-procedure.
The device instructions for use recommends that
stents be oversized by 1 to 2 mm with respect to
the reference vessel, and placed at least 1 cm below
the SFA origin and above the medial femoral epi-
condyle. Treatment of lesions in both legs was
permitted. Pre- and post-dilation and treatment of
inﬂow and outﬂow disease were at the physician’s
discretion.
The same antiplatelet regimen used in previous
studies was recommended for all patients: clopidog-
rel or ticlopidine starting at least 24 h before the
procedure, or a procedural loading dose; continued
clopidogrel or ticlopidine therapy for at least 60 days
post-procedure; and aspirin indeﬁnitely.
FOLLOW-UP ASSESSMENT. ABI and Rutherford
classiﬁcation were assessed before discharge and at
the 12-month clinical visit. Clinically driven target
lesion revascularization (TLR) was deﬁned as rein-
tervention performed for $50% diameter stenosis
within 5 mm of the target lesion after recurrent
clinical symptoms of PAD. Thrombosis was site-
reported as total occlusion of suspected thrombotic
origin. Stent integrity was assessed by radiography
at 12 months, with site-reported fractures reviewed
by a radiographic core laboratory for classiﬁcation
of fracture type. Clinical beneﬁt was deﬁned as
freedom from persistent or worsening symptoms
of ischemia (i.e., claudication, rest pain, ulcer, or
tissue loss) after the initial study treatment.
Patency was evaluated by duplex ultrasonography
at 12 months where physicians considered this
standard of care, with loss of patency correspond-
ing to a peak systolic velocity ratio $2.4. Deaths
were adjudicated by an independent clinical events
committee.
STATISTICAL ANALYSIS. The sample size of 900 was
selected to provide 95% conﬁdence for determination
of events at rates as low as 1% to 2%. The data were
analyzed using SAS 9.3 (SAS Institute, Cary, North
Carolina). Continuous variables were summarized
with means and SD, with p values calculated using
the standard t test. Dichotomous and polytomous
variables were reported as counts and percentages,
with p values calculated using the Fisher exact test.
As appropriate, the number of observations repre-
sented the number of patients, the number of treated
lesions, or the number of treated limbs. Kaplan-Meier
analyses were performed to assess freedom from
TLR, freedom from thrombosis, clinical beneﬁt, and
patency over time.
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273RESULTS
Between May 2012 and February 2013, 907 patients
were enrolled at 95 institutions in Japan. In total,
1,075 lesions were treated with 1,861 DES in these
patients. A mean of 1.7 stents per lesion, and a mean of
2.1 stents per patient, were implanted. The stents
used were 6 to 8 mm in diameter and 40 to 120 mm in
length. Demographics, comorbidities, and baseline
lesion characteristics reported by the investigative
sites are shown in Table 1. There was a 58.8% inci-
dence of diabetes, a 43.8% incidence of chronic kid-
ney disease, and a 21.5% incidence of critical limb
ischemia (CLI) in these patients. The lesions were
complex with an average lesion length of 14.7  9.7 cm
(range 0.5 to 40 cm), 41.6% total occlusions, and
18.6% in-stent restenosis (ISR).
SAFETY. Twelve-month follow-up was obtained for
787 patients, representing >95% of those eligible.
The DES was safe in Japanese patients. All-causeTABLE 1 Demographics and Lesion Characteristics
Patient characteristics
Patients, N 907
Mean age, yrs 73.5  8.5 (907)
Men 70.3 (638)
Diabetes 58.8 (533)
Hypertension 85.3 (774)
Hypercholesterolemia 60.9 (552)
Chronic kidney disease 43.8 (397)
eGFR <60 ml/min/1.73 m2 and/or dialysis 35.5 (322)
Pulmonary disease 8.0 (73)
Lesion characteristics
Lesions 1,075
Lesion length, cm 14.7  9.7 (1,074)
Lesions >15 cm 42.0 (451)
Lesions >20 cm 29.7 (319)
Lesion location*
Proximal SFA 61.1 (657)
Distal SFA 64.5 (693)
Popliteal 9.4 (101)
Total occlusion 41.6 (447)
In-stent restenosis 18.6 (200)
Percent diameter stenosis 91.9  10.7 (1,075)
Reference vessel diameter, mm 5.7  0.9 (1,075)
Critical limb ischemia (Rutherford classes 4–6)† 21.5 (218)
Number of patent runoff vessels‡
0 6.6 (71)
1 31.8 (340)
2 32.4 (347)
$3 29.2 (312)
Values are mean  SD (n) or % (n). *Of the 1,075 lesions in this study, 376 lesions
span more than 1 segment. †Rutherford classiﬁcation data not available for 60
lesions. ‡Data not available for 5 lesions.
eGFR ¼ estimated glomerular ﬁltration rate; SFA ¼ superﬁcial femoral artery.mortality was 5.1% through 12 months. There
were no device- or procedure-related deaths. No
paclitaxel-related adverse events were reported.
Seven patients in the study had an amputation for a
12-month rate of 0.8%. At the time of enrollment, 6
of the 7 patients had CLI with tissue loss (Rutherford
class 5). The 12-month Kaplan-Meier estimate of
freedom from TLR was 91.0% (Figure 1). The 12-
month Kaplan-Meier estimate of freedom from
thrombosis was 97.0%, with 6 cases reported within
30 days, 12 cases between 30 days and 6 months,
and 13 cases between 6 and 12 months of the study
procedure.
STENT INTEGRITY. At 12 months, 1,118 of 1,135 DES
(98.5%) were free from fracture, yielding a 12-month
fracture rate of 1.5% (17 of 1,135). The core labora-
tory classiﬁed the fractures as 5 Type I, 2 Type II,
1 Type III, and 9 Type IV (4).
CLINICAL OUTCOMES. Clinical assessment at
12 months revealed signiﬁcant improvement in
Rutherford classiﬁcation (p < 0.01) (Table 2). Clinical
improvement of at least 1 Rutherford class wasFIGURE 1 12-Month Freedom From TLR
The Kaplan-Meier curve shows 91.0% freedom from TLR through 12 months for patients
treated with the DES. The life table is included. DES ¼ drug-eluting stent(s); TLR ¼ target
lesion revascularization.
TABLE 2 Clinical Outcomes
Pre-Procedure Post-Procedure* 12 Months*
ABI 0.63  0.18 (974) 0.90  0.16 (691) 0.86  0.17 (824)
Rutherford class†
0 0.9 (9) 48.6 (352) 54.2 (427)
1 7.3 (74) 25.3 (183) 23.9 (188)
2 26.9 (273) 11.0 (80) 10.9 (86)
3 43.4 (441) 5.7 (41) 5.3 (42)
4 10.3 (105) 1.2 (9) 2.8 (22)
5 9.8 (99) 6.8 (49) 2.4 (19)
6 1.4 (14) 1.4 (10) 0.5 (4)
Values are mean  SD (n) or % (n). *Statistically signiﬁcant compared to pre-procedure, p < 0.01.
†Pre-procedure Rutherford class was obtained for 1,015 lesions, post-procedure Rutherford class
was obtained for 725 lesions, and 12-month Rutherford class was obtained for 788 lesions.
ABI ¼ ankle brachial index.
FIGURE 2 12-Mont
The Kaplan-Meier cu
treated with the DES
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274achieved in 638 of 757 patients (84.3%), w80% of
patients were classiﬁed as Rutherford class 0 or 1 at
12 months, and the median Rutherford classiﬁcation
improved from class 3 to class 0 (Table 2). Similarly,
the mean ABI also signiﬁcantly improved at
12 months from 0.63 to 0.86. Post-treatment clinical
beneﬁt, deﬁned as freedom from persistent orh Clinical Beneﬁt
rve shows 87.7% clinical beneﬁt through 12 months for patients
. The life table is included. DES ¼ drug-eluting stent(s).worsening symptoms of ischemia (i.e., claudication,
rest pain, ulcer, or tissue loss), was 87.7% at 12
months (Figure 2).
PATENCY. Duplex ultrasound was performed for
approximately 65% of patients. The DES was effective
in treating SFA lesions in Japanese patients. Based
on Kaplan-Meier estimates, the 12-month primary
patency rate was 86.4% (Figure 3). To evaluate
whether the ultrasound subset was representative of
the entire patient population, the demographics,
comorbidities, lesion characteristics, 12-month
freedom from TLR rates, and 12-month freedom
from thrombosis rates for patients who underwent
ultrasound were compared with those for patients
who did not undergo ultrasound, and no signiﬁcant
differences were found.DISCUSSION
The 1-year results of the present study demonstrate
the safety and effectiveness of the paclitaxel-coated
DES for the treatment of femoropopliteal PAD in a
large, real-world Japanese patient population with
numerous risk factors including high incidences of
diabetes, chronic kidney disease, and CLI. The le-
sions were also complex, including approximately
40% of lesions >15 cm and 30% >20 cm in length,
and a high rate of total occlusions and ISR. The low
frequencies of stent fracture and thrombotic occlu-
sion after DES placement reported in the present
study are comparable to the published rates for
nitinol BMS and to previous reports with the DES
(1,2,5–10). The freedom from TLR, clinical beneﬁt,
and patency results from the present study are
similar to previous clinical studies that evaluated the
DES in patients with femoropopliteal PAD. The pre-
vious studies included the Zilver PTX Randomized
Clinical Trial, which demonstrated the beneﬁt of the
DES compared with PTA or provisional BMS through
2 years (1,2). The results with the DES in the Japa-
nese subgroup from the randomized trial also
showed no major differences in safety and effec-
tiveness compared with the non-Japanese patient
group (10). Additionally, a complementary single-
arm study supported the performance of the DES in
a broader patient population than the randomized
trial (3). The results from the present study are
similar to the previously published results and
conﬁrm the beneﬁt of the DES despite the inclusion
of patients with increased risk factors and more
complex lesions.
Results with this DES were also recently reported
from the ZEPHYR (Zilver PTX for the Femoral Artery
FIGURE 3 12-Month Primary Patency
The Kaplan-Meier curve shows 86.4% primary patency through 12 months for lesions
treated with the DES. The life table is included. DES ¼ drug-eluting stent(s).
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6 Yokoi et al.
F E B R U A R Y 8 , 2 0 1 6 : 2 7 1 – 7 Zilver PTX Japan Post-Market Study Results
275and Proximal Popliteal Artery-Prospective Multi-
center Registry) study, which was designed to
examine the possible predictors of restenosis after
DES implantation (11). The ZEPHYR study involved an
even more challenging Japanese patient population
that included a larger percentage of diabetic patients
(69% vs. 59%) and critical limb ischemia patients (32%
vs. 22%), as well as a somewhat longer average lesion
length (17 cm vs. 15 cm), compared with the current
study. Furthermore, there are important differences
in the deﬁnitions, methodologies, and reporting
practices for the ZEPHYR study compared with the
current study and also compared with many previous
peripheral endovascular device studies, which rein-
force the difﬁculties in comparing results across
studies.
Other than the Zilver PTX randomized study (1,2),
there are currently no results available from ran-
domized controlled studies directly comparing this
DES to other endovascular therapies, and caution
must be taken when comparing outcomes between
different studies. Although not a randomized com-
parison, results from the current study of the DES,
such as the 12-month patency rate, compare favorably
to the limited available results with BMS in pop-
ulations including complex lesions, which report
patency rates ranging from 49% to 65% (9,12–14).
Differences such as patient demographics and lesion
characteristics can make comparisons between
studies difﬁcult, and in this regard, randomized
studies usually provide more meaningful compari-
sons. The previously published randomized study
showed signiﬁcant beneﬁt with the DES over BMS
(1,2). Despite the inclusion of more complex lesions,
the results with the DES in the current study are also
consistent with the DES results in the randomized
study.
Similarly, results from the current DES study, such
as the 12-month patency rate of 86.4%, compare
favorably to results for DCB, which range from 73.5%
to 89.5% (15–18). However, lesions in the DES study
were more challenging than those in the DCB
studies. For instance, the lesions in the DES study
were approximately twice as long, with approxi-
mately twice as many total occlusions, and included
ISR. Successful pre-dilation was also typically re-
quired before DCB treatment. Because of such dif-
ferences, comparisons between these studies should
be interpreted with caution. Previously published
results also show that the beneﬁt of the DES is sus-
tained over time (2); whereas, the long-term out-
comes with the DCB are limited to a small number of
patients (19). The 12-month patency rate from the
current study also compares favorably to the patencyrates, ranging from 51.1% to 78.0%, reported for
atherectomy (20,21).
STUDY LIMITATIONS. Stent thrombosis in the SFA
can be difﬁcult to distinguish from total occlusion
caused by restenosis because there is no standardized
classiﬁcation for SFA stent thrombosis unlike the ARC
classiﬁcation for coronary stent thrombosis (22).
Additionally, risk factors beyond the stented lesion,
for example, untreated residual inﬂow or outﬂow
stenosis or poor runoff, may contribute to the po-
tential for thrombosis within the infrainguinal ar-
teries. Due to these risk factors and the possible
inclusion of total occlusions that are of restenotic
rather than thrombotic origin, the site-reported rate
may overestimate the DES thrombosis rate in this
study. At longer times since the study procedure, the
likelihood that the occlusions were of restenotic
rather than thrombotic origin increases. Accordingly,
the cases reported within 30 days of the study pro-
cedure may be considered probable thromboses,
those cases reported between 30 days and 6 months
may be considered possible thromboses, and those
PERSPECTIVES
WHAT IS KNOWN? Experience with the Zilver PTX
drug-eluting stent in previous studies has shown
long-term beneﬁts, including a randomized controlled
trial that demonstrated superiority to standard care
(balloon angioplasty with provisional bare-metal
stent placement) and to bare-metal stents.
WHAT IS NEW? This large, all-comer, post-market
study conﬁrms the beneﬁts with this drug-eluting
stent and extends the results to more complex
patients, lesions, and risk factors.
WHAT IS NEXT? Further understanding of the
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276cases reported between 6 and 12 months may be
considered probable restenoses. Despite this possi-
bility for overestimation, the thrombosis rate through
12 months in this study was low and comparable to
the published rates for nitinol BMS as well as previous
reports with the DES, and demonstrates no increased
risk of stent thrombosis due to the paclitaxel drug
coating on the DES (1,2,5–10).
In this study, duplex ultrasonography was per-
formed by the investigative sites where physicians
considered this standard of care. As a result, patency
through 12 months was evaluated for a subset of
approximately 65% (702 1,075) of lesions. Additional
analyses indicated that the demographics, comor-
bidities, lesion characteristics, 12-month freedom
from TLR rates, and 12-month freedom from throm-
bosis rates for the ultrasound subset were not
signiﬁcantly different from those for patients who
did not undergo ultrasound. Therefore, the ultra-
sound subset adequately represents the overall study
population, supporting the validity of the patency
results.
Although this was a post-market, single-arm study
without an internal control group, the study enrolled
a large number of patients with symptomatic SFA
disease representing a real-world patient population.
The outcomes with the DES also remained similar to
those from the previously published randomized
study and similar to those from the complementary
single-arm study (1–3).results with drug-eluting stents compared with other
new therapies, such as drug-coated balloons and
resorbable stents, especially in long-term outcomes,
would provide valuable insights.CONCLUSIONS
Despite more challenging lesions, the results from
this real-world, post-market study are similar tooutcomes from the previous Zilver PTX studies,
conﬁrming the beneﬁt of the Zilver PTX DES.
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